Pharmaceutical Development Pipeline

Epidiolex®
Epidiolex
Dravet Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Epidiolex
Lennox-Gastaut Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Epidiolex
Tuberous Sclerosis Complex
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Sativex® (US)
Sativex
MS Spasticity
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
CBDV (GWP42006)
GWP42006 (CBDV)
Epilepsy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
GWP42006 (CBDV)
Autism Spectrum Disorders
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Other
GWP42003 (IV)
Neonatal Hypoxic-Ischemic Encephalopathy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
GWP42002 / GWP42003
GLIOBLASTOMA
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
GWP42003
Schizophrenia
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 

Medical Information

If you are a healthcare professional interested in additional scientific and clinical information on Greenwich Biosciences products, EPIDIOLEX, and cannabinoids, or would like to submit a medical request form

Visit Medical Information >

EPIDIOLEX CLINICAL TRIALS

For the most up-to-date list of publicly and privately supported clinical studies of human participants treated with EPIDIOLEX

VISIT ClinicalTrials.gov >